gefitinib has been researched along with trimetrexate in 3 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (trimetrexate) | Trials (trimetrexate) | Recent Studies (post-2010) (trimetrexate) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 422 | 50 | 21 |
| Protein | Taxonomy | gefitinib (IC50) | trimetrexate (IC50) |
|---|---|---|---|
| Dihydrofolate reductase | Mycobacterium avium | 0.3012 | |
| Dihydrofolate reductase | Homo sapiens (human) | 0.0207 | |
| Dihydrofolate reductase | Lacticaseibacillus casei | 0.1435 | |
| Dihydrofolate reductase | Saccharomyces cerevisiae S288C | 0.042 | |
| Dihydrofolate reductase | Escherichia coli K-12 | 0.1798 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.026 | |
| Dihydrofolate reductase | Pneumocystis carinii | 0.0378 | |
| Dihydrofolate reductase | Candida albicans | 0.04 | |
| Dipeptidyl peptidase 4 | Homo sapiens (human) | 0.01 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.008 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Toxoplasma gondii | 0.5788 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Trypanosoma cruzi | 0.0202 | |
| Dihydrofolate reductase | Rattus norvegicus (Norway rat) | 0.0794 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bansal, R; Malhotra, A | 1 |
2 review(s) available for gefitinib and trimetrexate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Therapeutic progression of quinazolines as targeted chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Enzyme Inhibitors; Humans; Molecular Structure; Neoplasms; Quinazolines | 2021 |
1 other study(ies) available for gefitinib and trimetrexate
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |